INBX – inhibrx, inc. (US:NASDAQ)
Stock Stats
News
Inhibrx Biosciences (NASDAQ:INBX) had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings.
Inhibrx: Ozekibart Beyond Chondrosarcoma, With Other Targeted Indications, Too [Seeking Alpha]
Inhibrx Advances Key Oncology Programs Toward Multiple 2026 Data Readouts [Yahoo! Finance]
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program [Yahoo! Finance]
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program
Form SCHEDULE 13G Inhibrx Biosciences, Filed by: BlackRock, Inc.
Form 8-K Inhibrx Biosciences, For: Dec 16
Form 10-Q Inhibrx Biosciences, For: Sep 30
Form 8-K Inhibrx Biosciences, For: Nov 14
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.